GLP-1 Agonists for Obesity—A New Recipe for Success?
JAMA · 26.03.2024 · 331 (12) · 1007
DOI: 10.1001/jama.2024.2252 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, erschienen am 26.03.2024. Verfasst von Dariush Mozaffarian. Beteiligte Einrichtung: Friedman School of Nutrition Science and Policy, Tufts University, Boston, Massachusetts. Hauptthemen laut MEDLINE: Glucagon-Like Peptide 1, Obesity, Anti-Obesity Agents. Die Arbeit wurde bisher 83-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
This Viewpoint discusses the drawbacks of using glucagon-like peptide 1 (GLP-1) agonists to treat obesity and presents an alternative approach of initial, staged GLP-1 agonist treatment supported by long-term lifestyle programming, including medically appropriate groceries or meals (“Food Is Medicine”), to address the cost, health, and equity burdens of obesity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Friedman School of Nutrition Science and Policy, Tufts University, Boston, Massachusetts.
- Division of Cardiology, Tufts Medical Center and Tufts University School of Medicine, Boston, Massachusetts.
Zitieren
APA
Mozaffarian, D. (2024). GLP-1 Agonists for Obesity—A New Recipe for Success?. JAMA, 331(12), 1007. https://doi.org/10.1001/jama.2024.2252
Vancouver
Mozaffarian D. GLP-1 Agonists for Obesity—A New Recipe for Success?. JAMA. 2024;331(12):1007. doi:10.1001/jama.2024.2252
BibTeX
@article{Mozaffarian2024,
author = {Mozaffarian, Dariush},
title = {GLP-1 Agonists for Obesity—A New Recipe for Success?},
journal = {JAMA},
year = {2024},
volume = {331},
number = {12},
pages = {1007},
doi = {10.1001/jama.2024.2252}
}
EUVIMED